Abbott Laboratories (ABT) Holdings Trimmed by Seaward Management Limited Partnership

Seaward Management Limited Partnership trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 969,681 shares of the healthcare product maker’s stock after selling 8,875 shares during the period. Abbott Laboratories accounts for 2.5% of Seaward Management Limited Partnership’s investment portfolio, making the stock its 7th biggest holding. Seaward Management Limited Partnership’s holdings in Abbott Laboratories were worth $51,742,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stock Yards Bank & Trust Co. grew its holdings in shares of Abbott Laboratories by 8.0% during the 2nd quarter. Stock Yards Bank & Trust Co. now owns 211,543 shares of the healthcare product maker’s stock valued at $10,283,000 after acquiring an additional 15,698 shares in the last quarter. Hexavest Inc. purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at $51,216,000. BKD Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 19.1% during the 2nd quarter. BKD Wealth Advisors LLC now owns 6,669 shares of the healthcare product maker’s stock valued at $324,000 after acquiring an additional 1,070 shares in the last quarter. America First Investment Advisors LLC grew its holdings in shares of Abbott Laboratories by 2.6% during the 2nd quarter. America First Investment Advisors LLC now owns 251,330 shares of the healthcare product maker’s stock valued at $12,217,000 after acquiring an additional 6,458 shares in the last quarter. Finally, Country Club Trust Company n.a. grew its holdings in shares of Abbott Laboratories by 0.5% during the 2nd quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock valued at $356,000 after acquiring an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 71.19% of the company’s stock.

Several research firms have recently commented on ABT. BMO Capital Markets restated a “market perform” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Barclays boosted their price target on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, September 28th. Bank of America restated a “buy” rating and set a $60.00 price target (up from $56.00) on shares of Abbott Laboratories in a report on Wednesday, October 4th. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Stifel Nicolaus boosted their price target on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, October 19th. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $60.24.

Abbott Laboratories (NYSE ABT) opened at $58.84 on Tuesday. The firm has a market cap of $102,416.96, a price-to-earnings ratio of 46.33, a price-to-earnings-growth ratio of 1.87 and a beta of 1.06. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 52-week low of $39.25 and a 52-week high of $59.60.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business’s revenue was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 EPS. equities analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a dividend of $0.28 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a yield of 1.90%. Abbott Laboratories’s payout ratio is currently 88.19%.

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the business’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $56.21, for a total transaction of $5,430,054.63. Following the completion of the transaction, the executive vice president now owns 142,082 shares of the company’s stock, valued at approximately $7,986,429.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the transaction, the insider now directly owns 10,256 shares of the company’s stock, valued at approximately $572,900.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 501,172 shares of company stock valued at $27,533,150. Company insiders own 0.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/16/abbott-laboratories-abt-holdings-trimmed-by-seaward-management-limited-partnership.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit